Preventive health, AI-driven science and shifting consumer behavior are reshaping how the world approaches aging and extending healthspan.
Aging has always been treated as something to manage at the edges, not as something to design around. That is changing fast.
According to new data from SNS Insider, the global longevity market is projected to grow from $27.61 billion in 2025 to $67.03 billion by 2035, driven largely by rising age-related health concerns worldwide [1]. In simpler terms, more people are not just living longer, but living longer with conditions they want to prevent, delay or better understand.
And that shift is turning longevity into an economic system built around one question: how do we stay healthier for longer, not just older?
The most important change in this market is not a breakthrough drug or a single technology. It’s a behavioral pivot. Across regions, healthcare is slowly shifting from reactive treatment to prevention. That means catching risk earlier, tracking biological changes over time and intervening before disease becomes entrenched.
Longevity tools are gaining traction as practical extensions of everyday healthcare. Traditional medicine often steps in when the body’s engine fails. Longevity, in contrast, is about monitoring wear and tear before a breakdown occurs.
That is reflected in the market structure. Preventive healthcare and wellness currently hold the largest application share, accounting for just over 30% of the market. It’s a sign that consumers are increasingly willing to invest in staying well, not just getting well.
The rise of the “self-managed” health era
One of the more striking insights from the report is the central role individuals have come to play. Consumers account for more than 35% of the market, the largest end-user segment. That means longevity is no longer confined to clinics, research labs or biotech pipelines. It’s now something people actively build into their lives.
Nutraceuticals and dietary supplements dominate the market, accounting for over 28% in 2025. While that might sound familiar, what’s different now is context. These products are no longer seen as fringe wellness tools, but as entry points into longer-term health strategies.
We are also seeing a strong shift toward direct-to-consumer ecosystems. People are no longer waiting for healthcare systems to “offer” longevity. They are purchasing it, subscribing to it and tracking it themselves.
In a way, longevity is becoming personalized infrastructure. Quiet, continuous and increasingly normalized.
Biology becomes data
Behind the consumer-facing layer, a more technical transformation is underway, but it’s worth translating. Fields like genomics and epigenetics are helping scientists understand not just what genes we have, but how those genes are switched on or off over time. If DNA is the script, epigenetics is the director deciding which scenes actually play out. This is why genomics and epigenetics currently dominate the technology segment, holding over 24% of market share.
At the same time, newer tools such as biomarker and aging-clock technologies are emerging rapidly. These systems attempt to estimate “biological age,” essentially asking whether your body is aging faster or slower than the calendar suggests.
It’s a bit like comparing a car’s mileage to how old it looks and performs. Two people might both be 50, but biologically, they could be in very different states of health. This kind of measurement is reshaping how longevity is defined, from something abstract into something trackable.
Experimental edge: targeting aging itself
Perhaps the most ambitious corner of the market lies in therapies that aim not just to treat disease, but to intervene in the aging process itself.
One of the fastest-growing areas is senolytics and senotherapeutics, approaches designed to target “senescent cells,” or damaged cells that stop functioning properly but don’t die off as they should. Over time, these cells accumulate and are believed to contribute to inflammation and age-related decline.
You can think of them as “stalled vehicles” clogging up a cellular highway. Clearing them is one way researchers hope to improve overall system flow.
This segment is projected to grow at the fastest rate in the coming decade, reflecting both scientific momentum and investor interest in what aging intervention might look like beyond symptom management.
Still, this remains a frontier space – promising, but early. Like much of longevity science, it sits between possibility and proof.
Geographically, the story is equally telling. North America currently leads the longevity market, holding nearly 40% share in 2025. The region’s strong biotech ecosystem, high consumer awareness, and established healthcare infrastructure continue to drive adoption.
However, the most rapid acceleration is happening elsewhere. Asia-Pacific is projected to be the fastest-growing region through 2035, driven by aging populations and rising healthcare awareness in China, Japan, South Korea and India.
The infrastructure behind the boom
The commercial growth projected by SNS Insider is mirrored by a robust and rapidly maturing biotech pipeline, visible through the lens of the DLT platform. According to the latest DLT landscape analysis, there are now 657 visible companies managing 2,785 tracked therapeutic assets, signaling that aging biology is no longer a niche interest but a deeply embedded industry pillar.
This market is broadening into a sophisticated, multi-mechanism platform. DLT’s granular tracking shows that cellular senescence alone is a target for 1,185 assets across 396 companies, while themes like chronic inflammation and altered intercellular communication appear even more frequently. While the US remains the primary anchor with 380 companies, DLT identifies significant international depth emerging from the UK, South Korea, France and Switzerland.
Ultimately, this suggests that as consumer demand for preventive health strengthens, the underlying biotech infrastructure – meticulously mapped by DLT – is already positioned to support a much larger longevity economy. For those looking to navigate this complex web of assets and players, the data suggests that the “frontier” is already becoming an established map.
Beyond the $67b number
It is easy to look at a projection like $67.03 billion by 2035 and treat it as just another market milestone, but the bigger story is the direction.
What we are witnessing is the gradual shift in the definition of aging itself: from something passive and inevitable to something measurable, manageable and increasingly influenced by science and technology. That is already visible in how people behave, from tracking sleep and metabolic health to experimenting with personalized nutrition and preventive therapies. It is also evident in how companies build products.
Yet, the most important nuance remains unchanged. Longevity is about extending the period of life where people feel capable, functional and well. If the past decade was about living longer, the next one may be about learning how to design the experience of aging itself.
The longevity market, beyond its valuation, becomes something larger. It is becoming a mirror of how we want to live, not just how long.
